TransCode Therapeutics In...

1.15
0.38 (49.35%)
At close: Mar 21, 2025, 3:59 PM
49.35%
Bid 1.06
Market Cap 797.21K
Revenue (ttm) 35.71K
Net Income (ttm) -707.7K
EPS (ttm) 5571.72
PE Ratio (ttm) n/a
Forward PE -2.23
Analyst Buy
Ask 1.07
Volume 213,773,100
Avg. Volume (20D) 2,603,123
Open 1.01
Previous Close 0.77
Day's Range 0.86 - 1.67
52-Week Range 0.65 - 66.33
Beta 1.15

About RNAZ

TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inh...

Industry Biotechnology
Sector Healthcare
IPO Date Jul 8, 2021
Employees 8
Stock Exchange NASDAQ
Ticker Symbol RNAZ
Full Company Profile

Analyst Forecast

According to 1 analyst ratings, the average rating for RNAZ stock is "Buy." The 12-month stock price forecast is $20, which is an increase of 1646.72% from the latest price.

Stock Forecasts

Next Earnings Release

TransCode Therapeutics Inc. is scheduled to release its earnings on Apr 4, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+27.18%
TransCode Therapeutics shares are trading higher a... Unlock content with Pro Subscription
2 months ago
+5.66%
TransCode Therapeutics shares are trading higher after the company announced the first patient third cohort dosing with TTX-MC138, its lead candidate for its Phase 1 clinical trial.